The latest from BioStock

» Elicera Therapeutics secures important EU patent
» Dr. Hoffmann presented Chordate Medical's results in the US
» Lipum accelerates clinical development
» Aqilion's chairman on the visions
» PHI charts a bold course to impact regenerative medicine

Read BioStock's newsletter for v.27 here.

Morning news

Iconovo increases sales efforts and secures production for ICOcap through a restructured agreement with.Read more.

Calliditas Therapeutics announces supportive interim data from Phase II study in head and neck cancer with lead NOX inhibitor candidate setanaxib. Read more.

Integral reports that a case study has been published in Science Translational Medicine. Read more.

Carbiotix announces that the last day for trading in warrants of series TO 1 is July 17, 2023. Read more.

PolarCool expands presence in professional British rugby through agreement with Bristol Bears. Read more.

Proby invites you to a conference call for the presentation of the company's Q2 report on July 18. Read more.

Idogen's Bankruptcy estate is offering the company's technology platform for sale starting July 13. Read more.

ADDvise Group announces preliminary results for Q2 2023 that are stronger than expected. Read more.

News since Wednesday lunch

90 percent of patients have completed their twelve-month follow-up in Stayble Therapeutics ongoing phase IIb study. Read more.

RaySearch Laboratories launched RayStation 2023B. Read more.

AstraZeneca announced that Enhertu has been approved in China as the first HER2-targeted treatment for patients with HER2-low metastatic breast cancer. Read more.

XVI has decided to end further patient enrollment in the study of PrimECC and strategic opportunities will now be evaluated. Read more.

Lipigon announced positive safety results from the Phase I study with Lipisense. Read more.

Invitation to presentation of ProstaLunds interim report for the second quarter of 2023. Read more.

Scandinavian ChemoTech renewed existing loans from external lenders, major shareholders, and board members and CEO. Read more.

Interim reports

Alligator Bioscience  Q-line  XVI  Bone support

This morning's price development

Winner: RLS Global +15%, Stayble Therapeutics +13,25%, Miris Holding +9,26%, Asarina Pharma +7,99%, Ascelia Pharma +5,93%

Förlorare: Cline Scientific -10,84%, Arcede Pharma -10,03%, Attana -7,36%, Redwood Pharma -6,59%, AroCell -6,43%

Index: OMSX30 +0,03% , Healthcare +0,09%

More from BioStock

» BioStock Coffee Break: Einar Pontén, CEO of Lipum
» Cline Scientific on the issue and next steps in StemCART
» The five best life science stocks of the first half of the year
» Lipum aims to complete Phase I study faster
» Respiratorius continues to strengthen VAL001